Nitric oxide (NO) is produced continuously from the endothelium and plays a pivotal role in the control of vascular tone. Many of the current therapeutic agents that increase blood flow through production of NO have to be taken orally and can produce significant adverse side effects. We now report on some novel NO-donor drugs, based on thiosugars that generate NO spontaneously. From the range of compounds synthesized, D-SNAG (S-nitroso-1-thio-2,3,4,6-tetra-O-acetyl-β-Dglucopyranose) was as effective a vasodilator as any other and, as it was the easiest to synthesize, we undertook a more detailed evaluation to understand the chemistry and mode of action of its vasodilator effect. From the chemical kinetic data, we found that NO release occurred predominantly by thermal decomposition, with a 20-fold increase in decomposition rate between 19 and 37
INTRODUCTION
Vascular endothelium continuously produces NO (nitric oxide) for the control of vascular tone in several vascular beds [1, 2] , including the skin [3] . Decreased skin blood flow, due to impaired NO-mediated vasodilatation, contributes to the vascular problems associated with disorders such as diabetes mellitus [4] and Raynaud's phenomenon [5] . As NO is soluble in both lipids and water, it passes readily from cell to cell. However, it is a gas and inconvenient for direct delivery to the skin circulation. Current therapeutic agents that increase blood flow through the NO pathway have significant drawbacks. Most have to be taken orally and can produce significant adverse side effects, such as headaches and flushing [6] . We now report details on the chemical activity and vascular effects of a novel topically-applied NO-releasing drug, d-SNAG (S-nitroso-1-thio-2,3,4,6-tetra-O-acetyl-β-d-glucopyranose), derived from 1-thio-2,3,4,6-tetra-O-acetyl-β-d-glucose. We chose nitrosated thiosugars for examination because of the success of GTN (glyceryl trinitrate) as a transdermally delivered NO-donor drug. GTN patches are used in the management of angina. However, GTN differs from a nitrosated thiosugar in that the former has to be metabolized to produce NO, while the latter releases NO spontaneously.
In a previous publication [7] , we described the preparation of a number of NO-donor compounds derived from thiosugars. Elsewhere, we gave a preliminary account of the vasodilator effects of one of these compounds on human skin microvessels [8] . However, the chemical instability of these compounds resulted in a lack of 
reproducibility and made them unsuitable, at that time, as reliable research and therapeutic agents. We have recently made significant changes to the method of synthesis in order to achieve much greater stability. While it proved impossible to isolate the compounds as solids, the novel nitrosation procedure used gave us ethanolic solutions of a number of S-nitrosothiosugars that were stable over several days at ambient temperatures, and indefinitely in a − 80 • C freezer. The purpose of the present study, therefore, was to investigate the vascular activity of the newly synthesized d-SNAG in humans. In particular, we tested the dose dependency and reproducibility of the vascular response. We also studied the chemistry of d-SNAG and 16 other S-nitrosothiosugars to help us gain a better understanding of the mechanisms of the vasodilatory action. Although none of the compounds we examined proved better in its vasodilator action than that derived from 1-thio-2,3,4,6-tetra-O-acetyl-β-d-glucopyranose, results from work with other thiosugars contributed to our understanding regarding the mode of action of these compounds, and these results will be described only briefly.
METHODS

Chemical studies
Synthesis
Thiosugars were prepared by literature methods or by modification of literature methods, and characterized by the usual range of spectroscopic techniques (details of which will be published elsewhere, and can be obtained from A.R.B. on request). 'Nitrous fumes' (largely N 2 O 4 ), obtained by dropwise addition of concentrated HCl to ground sodium nitrite, were passed via a calcium chloride tube into a solution of the thiosugar in HPLC-grade ethanol for 2 min, during which time the solution turned bright red. Attempts to isolate the S-nitrosated thiosugar resulted in decomposition, however mild the procedure. Consequently, the solution was instead flushed with argon for 4 min to remove any unreacted nitrous fumes and then filtered through dry potassium carbonate to remove any acid formed during the reaction. In ethanolic solution, the products were stable enough for UV analysis, and since ethanol/water was the vehicle of choice for the vascular studies, isolation was unnecessary. Therefore sample preparation before administration to the skin required only the addition of an equal volume of water.
The complete range of compounds studied is displayed in Table 1 , together with the sugar from which they were derived. There is a rationale behind each of the sugars chosen. d-SNAG was selected because it is derived from one of the most readily available sugars (d-glucose); for the study of the effects of lipophilicity on transdermal drug delivery, d-SNAG was modified to give d-SNOPROP, d-SNOBUT, d-SNOVAL, d-SNOHEX and d-SNOG (the non-acetylated form of d-SNAG) (see Table 1 for the chemical names of these drugs).
As a simple equatorial-to-axial change at the 4-position makes galactose so much more soluble than glucose in ethanol/water, we prepared the nitrosated form of acetylated thiogalactose, d-SNAGAL. When copper (I) ions catalyse the release of NO from SNAP (S-nitroso-N-acetylpenicillamine), the metal ions bind to the nitrogen of the N-acetyl group to form a six-membered intermediate site. We wanted to examine the role of metal ions in the release of NO from S-nitrosated thiosugars, and so made d-SAGA and d-SAGAL (from glucosamine and galactosamine respectively) where similar binding could occur. This was compared against d-SNAG, in which the copper ion would have to bind to the oxygen of the O-acetyl group. Of the other sugars chosen, d-xylose was a popular option, as it occurs in the skin, and so we made d-and l-SNAX, which allowed us, additionally, to look for possible enzyme involvement in NO release. The same rationale was behind the synthesis of d-and l-SNARB from arabinose. To examine the efficacy of disaccharides, we made d-SNAL and d-SNAM from d-lactose and d-maltose respectively. The synthesis of 6-d-SNAG allowed us to observe the effect of moving the SNO group away from the anomeric position (on to the 6-position of the sugar ring) while still generating a six-membered copper complexation site. In this slightly different case, the complex relies heavily on the potential of the ring oxygen to act as an electrondonating substituent. d-SNOB gives us a nitrosated thiosugar with benzoyl protecting groups rather than four acetyl groups. Such groups are readily metabolized, and therefore they were included in the series for comparative purposes.
The release of NO from an S-nitrosated thiosugar is due to the formation of a disulphide [9] . The decomposition of d-SNAG and all other thiosugars reported in the present work follows the reaction pathway shown in Scheme 1: 2 mol of NO and 1 mol of disulphide result from the decomposition of 2 mol of S-nitrosothiosugar.
Kinetic studies
As all vascular testing was performed using ethanol/water (1:1, v/v) as the solvent, this was also used for the chemical studies. The kinetics of decomposition were measured by monitoring the decrease in absorbance at 345 nm, characteristic of the -SNO group, as a function of time. To provide a conveniently high absorbance, the initial concentration of S-nitrosothiosugar was set at 2.4 mmol/l. Data for the reaction of d-SNAG, were obtained at four temperatures, 19, 25, 32 and 37
• C, corresponding to the temperature of the vascular testing laboratory, standard room temperature, approximate skin temperature and body temperature respectively.
As a helium/neon laser was used to monitor skin blood flow, the effect of light on d-SNAG decomposition was examined. Three different wavelengths were chosen, 345.6, 558.4 and 638 nm, corresponding to the two peaks in the UV-visible spectrum of a nitrosothiol and the wavelength of the laser of the Doppler imager respectively. All such experiments were carried out at a room temperature of 19
• C to reduce the effect of thermal decomposition.
In a series of previous chemical studies, it was found that even low concentrations of copper ions had a dramatic effect on the release of NO from S-nitrosothiols [10] . The true catalytic species is Cu + , even if Cu 2+ ions are added. There is sufficient thiol present, from the hydrolysis of the nitrosothiol, to effect reduction of Cu 2+ to Cu + [11] . To see if Cu + ions had a similar effect on S-nitrosothiols from thiosugars, the effect of copper sulphate (10 µmol/l) on the release of NO from d-SNAG was examined.
Addition of a thiol to a solution of d-SNAG could result in the transfer of the NO group (as NO + ) to a new thiol (transnitrosation). This matter was examined using cysteine because of its presence in biological tissue. S-Nitrosocysteine decays rapidly in the presence of copper (10 µmol/l), and so a model was devised using d-SNAG (2.4 mmol/l) and cysteine (2.4 mmol/l) in the presence of an equivalent amount of copper (10 µmol/l). Due to the very different rates at which cysteine and SNAG decompose in the presence of copper, we were able to study whether the NO from SNAG could transnitrosate cysteine.
Lipophilicity studies
Lipophilicity is a key factor in drug delivery, and particularly in transdermal delivery, owing to the highly hydrophobic barrier presented. Its measurement, termed log P, is calculated for a given compound by determining its ability to partition between various proportions of octanol and water. Using potentiometric titration (Sirius PCA 101; Sirius Analytical Instruments Ltd) and shake flask techniques (in combination with UV spectroscopy and Ellman's reagent), we were able to determine the log P values of this group of thiosugars. The use here of precursors to the S-nitrosothiols was based purely on stability grounds and with the knowledge that NO functionality would not greatly influence the overall log P value. A high positive value suggests that the compound prefers to sit in the octanol layer, whereas a low or negative reading relates to compounds that occupy the aqueous layer to a greater extent. This can, in turn, be related to an in vivo system and enable us to predict the former type of compound to reside in lipophilic tissue, while the latter type is more likely to deposit in hydrophilic regions of the body. To increase the lipophilicity of d-SNAG, propionylated, butyrionylated, valerionylated and hexionylated side arms replaced the acetyl groups at the 2-, 3-, 4-and 6-positions. In addition, the non-acetylated version of d-SNAG, known as d-SNOG, was synthesized. Owing to the lowered solubility in ethanol/water of the more lipophilic members of this group, we were unable to measure the rate of NO release by the use of UV-visible spectroscopy. Instead we used an NO-sensitive electrode (ISO-NO sensor; World Precision Instruments) to compare the amounts of NO formed from d-SNAG and an equivalent concentration of d-SNOVAL.
Vascular studies
Subjects
We recruited eight healthy male volunteers to take part in a repeat visit study that was approved by the Tayside Committee on Medical Research Ethics. All the volunteers gave written, informed consent to participate. The healthy volunteers were aged between 20 and 35 years, were non-smokers, were not taking concomitant medication, and had no history of cardiovascular disease.
Laser Doppler perfusion imaging
We measured microvascular perfusion using laser Doppler imaging (Moor LDI; Moor Instruments Ltd). A 2 mW helium/neon laser scans the surface of the skin, and light back-scattered from moving erythrocytes is shifted in frequency by an amount proportional to their velocity, according to the Doppler principle. These Doppler shifts are collected and processed by the instrument. For each scan the computer builds up a colour-coded image representing skin perfusion in two dimensions. The relative measure of volume flow is called the laser Doppler flux and is expressed in arbitrary perfusion units (PU). The laser head was positioned 50 cm from the measurement site, with a hood mirror deflecting the beam on to the skin surface. The scan region encompassed all four delivery sites, and each scan took approx. 1 min.
The recorded images were analysed using dedicated image processing software (Moor Instruments Ltd). For each time, we calculated the median laser Doppler flux in the area of skin enclosed by each ring, so building up a response-time curve. For repeat measurements we evaluated the area under 10 min portions of the response curve at each dose, with respect to baseline flow, as an index of each phase of the total response.
Assessment of vascular responses
Experiments were conducted in a thermostatically controlled room at 19 + − 1
• C, and the subjects were seated with their arms supported at heart level. The drug, in a vehicle of ethanol/water (1:1, v/v), was contained in Perspex rings of internal diameter 20 mm that were fixed adjacent to one another on the forearm using doublesided adhesive tape. Liquid on the surface of the skin causes a small artifactual increase in the laser Doppler signal, due to spectral reflection, so a baseline blood flow measurement was taken with 1 ml of the ethanol/water (1:1, v/v) mixture in each ring to take account of this. After removing the vehicle, 1 ml of each drug or 1 ml of control solution [ethanol/water (1:1, v/v), thiol or disulphide] were placed in separate rings, and blood flow measurements were taken every 1 min to follow the developing response. Owing to the low solubility of the more lipophilic compounds, we used KY jelly as the vehicle for these and for a corresponding ethanol control. The changes in perfusion were monitored for up to 40 min. The participants were blinded as to which solution was being tested at any time.
Statistical analysis
The Shapiro-Wilk test showed that the blood flow variables had a normal distribution. We used repeatedmeasures ANOVA to determine the statistical significance of differences between different concentrations of drug. To express the reproducibility of the measurements for one drug within individuals, we calculated the coefficient of variation of the response to d-SNAG measured on two occasions for each 10-min phase of the response and for each subject. To evaluate the betweensubject variability, we calculated the mean of two measurements and then derived the coefficient of variation for the subject group as a whole. Table 2 shows the in vitro decomposition from some selected S-nitrosated thiosugars. There was relatively little change in the rate at which NO was released. Additionally, the enantiomeric pairs d/l-SNAX and d/l-SNARB decomposed at similar rates. Figure 1 shows that temperature had a dramatic effect on the decomposition of d-SNAG. There was a 20-fold increase in decomposition rate on going from 19 to 37
RESULTS
Kinetic studies
• C. There was relatively little effect of light or copper ions on the decomposition of d-SNAG.
Table 2 In vitro decomposition of selected S-nitrosated thiosugars measured by UV spectroscopy
The half-life is the time taken for half of the test compound to decompose, releasing free NO, while being maintained at 25
• C in an ethanol/water (1:1, v/v) solution. The chemical names of the compounds are listed in Table 1 . Figure 2 shows that the decomposition of S-nitrosocysteine alone and of d-SNAG in the presence of copper was minimal over 3 h. S-Nitrosocycteine in the presence of copper showed a greater degree of decomposition, as did d-SNAG in the presence of both cysteine (2.4 mmol/l) and copper, suggesting that transnitrosation is taking place.
Test compound Half-life (h)
D
Table 3 Variation of lipophilicity for a series of S-nitrosated thiosugars
Clog P (-SH) refers to log P data calculated for the precursor thiols by computational methods. Clog P (-SNO) refers to data calculated in the same way but for the S-nitrosothiol, while log P (-SH, exp) data were obtained experimentally. The chemical names of the compounds are listed in Table 1 .
Compound
Clog P (-SNO) Clog P (-SH) log P (-SH, exp) Table 3 shows that the log P value increased with the addition of extra acetyl side arms, indicating greater lipophilicity. Using computational predictions, a value could also be calculated for the pre-and post-nitrosated species, with the former agreeing closely with the experimental data (Table 3 ). Figure 3 shows that the more lipophilic derivative d-SNOVAL released NO more slowly than did d-SNAG.
Vascular studies
Vascular responses over 30 min for the three concentrations of d-SNAG (0.25 %, 0.5 % and 0.75 %) are shown in Figure 4 . ANOVA shows that there was a significant dose effect (P = 0.001), which was greatest in the first 20 min of the response. There was good reproducibility of the vascular response to 0.75 % d-SNAG on repeated testing. The intra-subject coefficient of variation was calculated to be 19 % and the inter-subject variation was 16 %. In the presence of copper, peak vascular responses to 0.75 % d-SNAG were not significantly different from those when copper was absent (113 + − 3 
DISCUSSION
S-Nitrosothiols are vasodilators because they release NO [12] . Due to the reported instability of these compounds, biologists frequently overlook their therapeutic potential. Instead, exogenous NO sources, such as organic nitrates, nitrites, nonoates, nitrosamines and organotransition metal nitrosyl complexes [13] , as well as simple NOgenerating systems [14, 15] , are more commonly discussed. We therefore examined the in vitro release of NO from the compounds listed in Table 1 . In comparable studies with S-nitrosated amino acids [16] the reactions were fast enough to follow to completion and to ascertain that they were accurately of the first order in reactant. This was not possible in the current situation, where the reactions were much slower, and so we measured the changes in absorbance at 345 nm, due to fission of the S-N bond, over the first 10 h of the reaction. The half-lives were calculated by the method of Swinbourne [17] and Kedzy et al. [18] , assuming that the reactions were of the first order. It can be seen that, in spite of the wide variation in structure, the halflives were shown to be similar. We have also shown that the rate constant for d-SNAG decomposition is not concentration dependent (R. J. Pearson and A. R. Butler, unpublished work).
In our pilot work, all of the compounds listed in Table 1 were examined for vasodilator action in the forearms of healthy volunteers. All showed similar effects and resulted in an approx. 5-fold increase in perfusion over 30 min. Changing the thiosugar protecting group from acetyl to benzoyl (d-SNOB) had only a small effect, as was the case with the SNO group at the 6-position (6-d-SNAG). Vasodilators derived from disaccharides (d-SNAL and d-SNAM) were neither significantly better nor poorer than those derived from monosaccharides. While the compounds all produced a similar peak response, they did differ in the time taken to reach a plateau. This parallels exactly the in vitro release of NO. The other point to note is that, as expected, the enantiomeric pairs d/l-SNAX and d/l-SNARB decomposed at similar rates. It has been suggested that there is an enzyme responsible for the release of NO from a nitrosothiol [19] , but, in view of the similar effects obtained with both the d-and l-forms of SNAX and SNARB, this is unlikely to be the case with this class of compounds.
The data in Table 3 show a wide range of log P values. Whereas it would have been interesting to compare the log P value with vascular activity, the large variation in NO release between d-SNAG and d-SNOVAL, measured by a NO sensor, highlighted an extra variable. From our pilot work, had any of these compounds proved to be a better vasodilator than d-SNAG, this avenue would have been studied further. However, d-SNAG is as good as all the others, and by far the easiest to make. So, in the more detailed evaluation of nitrosated thiosugars as vasodilators, we limited our work to d-SNAG. The enhanced stability of the newly synthesized d-SNAG was reflected in the vascular studies. We were able to demonstrate a very clear dose-response relationship. Particularly important was the good reproducibility of the vascular response to d-SNAG on repeated testing. The intra-and inter-subject variabilities of 19 % and 16 % respectively are better than those achieved by us for the NO donor sodium nitroprusside (25 % and 24 % respectively), delivered transdermally to the skin by the technique of iontophoresis (F. Khan, unpublished work). The thiol from which the S-nitrosated thiosugar was made and the disulphide formed on NO release had no vasodilator action.
Based on the kinetic data, we propose that, for S-nitrosated thiosugars, NO release occurs predominantly due to thermal decomposition, and it is this chemical reaction that is responsible for the vasodilator effect. Evidence to support a thermal route for the in vitro release of NO from S-nitrosated thiosugars comes from the finding of a 20-fold increase in decomposition rate on going from 19
• C to 37
• C. This high activation energy explains why d-SNAG is stable indefinitely in a freezer at − 80
• C, but is an active NO vasodilator at body temperature. Due to the effect of temperature, we ensured that all subjects had at least a 30 min period of equilibration to room temperature before vascular testing, to minimize significant variations in skin temperature. Given the relative stability of forearm skin temperature, it is unlikely that small differences in skin temperature (which we find can vary between 32 and 34
• C) would have had any significant effect on the vasodilator response to d-SNAG. Furthermore, it can be seen from Figure 1 that, over the time course of our study, it is unlikely that these small differences would have any real significant effect on the decomposition of SNAG.
Light is known to effect release of NO from S-nitrosated amino acids [20] , but its effect on the decomposition of d-SNAG was found to be very small. This improves the potential usefulness of such a compound in terms of its therapeutic potential.
The dominant pathway for NO release from S-nitrosated amino acids is via catalysis by copper ions; the mechanism involves complexation of the metal ion to the nitrogen atom of NO and to the oxygen/nitrogen of the amino acid. However, we found that adding copper ions had only a very small effect on the decomposition of d-SNAG. Of course, with d-SNAG there is no N-acetyl group to provide a nitrogen atom for complexation, and this could explain the small effect of added copper ions. We therefore examined the effect of added copper ions on the decomposition of d-SAGA and d-SNAGAL, where there is a nitrogen atom ripe for complexation ( Figure 5 ), but again the effect was small.
Even if thermal release of NO is responsible for vasodilatation, the delivery of that NO might occur in one of a number of ways: (1) release of NO by thermal decomposition in the well on the forearm and diffusion across the epidermis; (2) entry of the drug into the epidermis and migration to the hypodermis, where there is thermal release of NO; (3) transnitrosation of the drug to cysteine in the skin and subsequent release of NO from S-nitrosocysteine; and (4) entry of the drug into the epidermis, thermal decomposition to release NO and migration of NO to the blood vessels of the hypodermis. Routes 2 and 4 are consistent with our preliminary observations using skin layer stripping and X-ray photoelectron spectroscopy to show an enhanced amount of sulphur in only the first, second and third layers of the epidermis. However, in view of the very shallow penetration, we think that these are minor routes, and that the major cause of vasodilatation is probably route 1, although we cannot rule out the operation of route 3.
It is known that S-nitrosated compounds can undergo transnitrosation with a thiol [21] :
The ability of NO to transfer between different thiols gives rise to the potential for transnitrosation from our S-nitrosothiosugar to an endogenous thiol, such as cysteine, which can then act as an NO store. If the newly formed S-nitrosothiol (R SNO in the above equation) is more prone to decomposition than the original one, transnitrosation will amount to catalysed NO release. The addition of cysteine (2.4 mmol/l) to a solution of d-SNAG (2.4 mmol/l) resulted in greatly enhanced release of NO. The reaction was complete in 1 h. S-Nitrosocysteine is very susceptible to copper ioncatalysed release of NO [22] , but our preliminary data showed that addition of copper ions to the well on the forearm had little effect on the vasodilator action of d-SNAG. Thus we could find no independent evidence for the formation of S-nitrosocysteine in skin. Routes 2, 3 and 4 (listed above) would be influenced by changes in the lipophilicity of the drug, and so we synthesized a series of S-nitrosated thiosugars in which the protecting groups at the 2-, 3-, 4-and 6-position of the thiosugar were changed. The use of the thiosugars was necessary owing to the thermal instability of the nitrosated compounds. However we used a computational technique (CLOGP) to calculate the log P values of the nitrosated compounds [23] . To check the validity of this procedure we also used CLOGP to calculate the log P values of the thiosugars from which the nitrosated compounds were derived, and then compared the experimental values with those calculated. The agreement is good, and this gives us confidence in the calculated values for the nitrosated compounds.
In summary, we have described the chemical and vascular properties of novel NO donors based on thiosugars. These NO donors are stable, and liberate NO spontaneously without enzymic conversion. From the range of NO donors synthesized, d-SNAG was the most desirable as a vasodilator and produced reproducible vascular effects. It would appear that NO release occurs predominantly by thermal decomposition, and it is this chemical reaction that is responsible for the vasodilator effect. The delivery of the released NO to the microvessels of the forearm skin most probably occurs by diffusion across the epidermis. These compounds could have potentially exciting applications in conditions associated with excessive constriction of peripheral vessels, such as Raynaud's phenomenon. Additionally, they might provide an attractive source of localized NO delivery without inducing systemic side effects.
